CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 540 enrolled
Drug / intervention
bupropion hydrochloride +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00666978
NCT00666978Phase 4Completed

Enhancing Tobacco Use Treatment for African American Light Smokers

Lisa Sanderson Cox, PhD·interventional·Posted Apr 25, 2008·Updated Nov 13, 2017

In Brief

A Phase 4 clinical trial evaluating smoking cessation intervention, bupropion hydrochloride, and 5 other interventions for Bladder Cancer and 10 related conditions. Completed, enrolled 540 participants across 2 sites.

Detailed Summary

RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking. PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.

Study Details

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 25, 2008
Enrollment StartDec 1, 2007
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.2 years ago

Interventions

smoking cessation interventionbehavioral

bupropion hydrochloridedrug

gene expression analysisgenetic

polymerase chain reactiongenetic

counseling interventionother

educational interventionother

psychosocial assessment and careprocedure